Upon joining the study, consent is required. If unable to provide consent, a trusted person or loved one may do so. In urgent situations, the investigator may include the patient with subsequent consent needed to continue.

The study involves the use of a solution called Regiocit, which contains sodium chloride and sodium citrate. This solution is administered through a vein, a process known as intravenous administration.

The goal is to evaluate the effectiveness of a treatment called regional citrate anticoagulation during a procedure known as continuous extra-renal purification in intensive care.

Throughout the study, the level of calcium in the blood after it passes through a filter is monitored. The target calcium levels are between 0.35-0.45 mmol/l or 0.25-0.35 mmol/l.

The primary focus is to observe the incidence of filter thrombosis, which is when a blood clot forms in the filter.

The lifespan of each filter used in the procedure is measured in hours. Reasons for stopping the procedure are recorded, such as filter thrombosis, catheter issues, or the end of the session after more than 72 hours.

Other factors monitored include the rate of citrate infusion, the occurrence of metabolic complications, and the costs associated with filter changes.

The study is estimated to conclude by July 1, 2025. Participation involves regular monitoring and adjustments as needed to ensure the effectiveness and safety of the treatment.